Cytotoxicity of tamoxifen and its major metabolites in breast cancer cell lines;Cytotoxicite du tamoxifene et de ses principaux metabolites sur lignees cellulaires d'adenocarcinomes mammaires humains

Bulletin du Cancer

Volumn 83, Issue 10, 1996, Pages 809-815

  Bachmann Moisson, N ^a   Barberi Heyob, M ^a   Merlin, J L ^a   Ledrich, M L ^a   Batt, A M ^b   Guillemin, F ^a  

^a CENTRE ALEXIS VAUTRIN   (France)

^b Centre du Medicament URA CNRS 597   (France)

Author keywords

in vitro; metabolites; resistance; tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; DRUG METABOLITE; ESTRADIOL; ESTROGEN RECEPTOR; NORTAMOXIFEN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; TUMOR CELL LINE;

EID: 0029816840     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Adam HK, Douglas EJ, Kemp JV. The metabolism of tamoxifen in humans. Biochem Pharmacol 1979;27:145-52
2. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemichal analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-9
3. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: implication concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 1986;83:2496-500
4. Bonneterre J. Meta-analyse des traitements medicaux adjuvants dans les cancers du sein. Resultats à10 ans. Bull Cancer 1992;79:459-64
5. Borgna JL. Contribution àl'élucidation du mécanisme d'action antiŒstrogènique et antitumoral du tamoxifène. Bull Cancer 1994;81:29-37
6. Clarke R, Van den Berg HW, Murphy RF. Tamoxifen and 17ß-estradiol reduce the human fluidity of human breast cancer cells. J Natl Cancer Inst 1990;82:1702-5
7. Coradini D, Cappelletti V, Granata G, Di Fronzo G. Activity of tamoxifen and its metabolites on endocrine-dependent and endocrine-independent breast cancer cells. Tumor Biol 1991;12:149-58
8. Daffada AAI, Johnston SRD, Smith IE, Detre S, King N, Dowsett M. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res 1995;55:288-93
9. Danielian PS, White R, Hoare SA, Fawell SE, Parker MG. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 1993;7:232-40
10. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 1978;38:3352-64
11. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 1989;320:479-84
12. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25:127-205.
13. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988; 48:5183-7
14. Greenberg DA, Carpenter CL, Messing RO. Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC-12 neurosecretory cell line. Cancer Res 1987;47:70-4
15. Hull DF, Clark GM, Osborne CK. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983;43: 413-9
16. Jiang SY, Parker CJ, Jordan VC. A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens. Breast Cancer Res Treat 1993;26:139-47
17. Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F. Identification of the cytochrome p450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991;41: 1911-9
18. Jordan VC, Bain RR, Brown RR, Gordon B, Santos MA. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res 1983;43: 1446-50
19. Jordan VC, Wolf MF, Mirecki DM. Hormone receptors assays: Clinical usefulness in the management of the carcinoma of the breast. Crit Rev Clin Lab Sci 1988;26:97-152
20. Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994;54:349-53